ADC ID	DRG0OUXWT
ADC Name	Rolinsatamab talirine
Synonyms	rolinsatamab talirine; ABBV-176    Click to Show/Hide
Organization	AbbVie (Top20 MNC) (Originator)
Drug Status	Phase 1 (discontinued)
Drug-to-Antibody Ratio	2
Structure
	3D MOL			2D MOL
Antibody Name	Rolinsatamab					Antibody Info
Antigen Name	Prolactin receptor (PRLR)					Antigen Info
Payload Name	SGD-1882					Payload Info
Therapeutic Target	Human deoxyribonucleic acid (hDNA)					Target Info
Linker Name	Mc-Val-Ala					Linker Info
Conjugate Type	Reactive Cysteines
Combination Type	talirine

Standard Type	Value	Units	Description	Reference
Maximum Observed Concentration (Cmax)	47.7	ng/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 2.7 ug/kg, n=3.	[1]
Time to Maximum Concentration (Tmax)	0.3	h	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 2.7 ug/kg, n=3.	[1]
Area Under the Concentration-Time Curve (AUC)	0.335	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 2.7 ug/kg, n=3, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	0.32±0.49	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 2.7 ug/kg, n=3, AUCinf.	[1]
Maximum Observed Concentration (Cmax)	78.8	ng/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 4.05 ug/kg, n=1.	[1]
Time to Maximum Concentration (Tmax)	0.4	h	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 4.05 ug/kg, n=1.	[1]
Area Under the Concentration-Time Curve (AUC)	0.81	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 4.05 ug/kg, n=1, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	0.9	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 4.05 ug/kg, n=1, AUCinf.	[1]
Maximum Observed Concentration (Cmax)	103	ng/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 6.075 ug/kg, n=2.	[1]
Time to Maximum Concentration (Tmax)	0.4	h	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 6.075 ug/kg, n=2.	[1]
Area Under the Concentration-Time Curve (AUC)	1.16	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 6.075 ug/kg, n=2, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	1.31	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 6.075 ug/kg, n=2, AUCinf.	[1]
Maximum Observed Concentration (Cmax)	356	ng/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 12.15 ug/kg, n=1.	[1]
Time to Maximum Concentration (Tmax)	2	h	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 12.15 ug/kg, n=1.	[1]
Area Under the Concentration-Time Curve (AUC)	6.34	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 12.15 ug/kg, n=1, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	6.67	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 12.15 ug/kg, n=1, AUCinf.	[1]
Maximum Observed Concentration (Cmax)	428	ng/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 24.3 ug/kg, n=2.	[1]
Time to Maximum Concentration (Tmax)	0.6	h	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 24.3 ug/kg, n=2.	[1]
Area Under the Concentration-Time Curve (AUC)	9.2	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 24.3 ug/kg, n=2, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	9.99	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 24.3 ug/kg, n=2, AUCinf.	[1]
Maximum Observed Concentration (Cmax)	1140	ng/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 36.45 ug/kg, n=2.	[1]
Time to Maximum Concentration (Tmax)	4	h	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 36.45 ug/kg, n=2.	[1]
Area Under the Concentration-Time Curve (AUC)	27.7	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 36.45 ug/kg, n=2, AUClast.	[1]
Maximum Observed Concentration (Cmax)	0.85	ng/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 50 ug/kg, n=2.	[1]
Time to Maximum Concentration (Tmax)	2	h	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 50 ug/kg, n=2.	[1]
Area Under the Concentration-Time Curve (AUC)	16.7	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 50 ug/kg, n=2, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	17.8	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 50 ug/kg, n=2, AUCinf.	[1]
Maximum Observed Concentration (Cmax)	1600	ng/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 72.9 ug/kg, n=2.	[1]
Time to Maximum Concentration (Tmax)	2	h	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 72.9 ug/kg, n=2.	[1]
Area Under the Concentration-Time Curve (AUC)	93.3	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 72.9 ug/kg, n=2, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	93.3	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 72.9 ug/kg, n=2, AUCinf.	[1]
Maximum Observed Concentration (Cmax)	1560	ng/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 78.3 ug/kg, n=1.	[1]
Time to Maximum Concentration (Tmax)	4	h	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 78.3 ug/kg, n=1.	[1]
Area Under the Concentration-Time Curve (AUC)	89.6	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 78.3 ug/kg, n=1, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	89.6	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 78.3 ug/kg, n=1, AUCinf.	[1]
Maximum Observed Concentration (Cmax)	1560	ng/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 99.9 ug/kg, n=2.	[1]
Time to Maximum Concentration (Tmax)	1.1	h	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 99.9 ug/kg, n=2.	[1]
Area Under the Concentration-Time Curve (AUC)	38	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 99.9 ug/kg, n=2, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	38	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 99.9 ug/kg, n=2, AUCinf.	[1]
Maximum Observed Concentration (Cmax)	2530	ng/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 109 ug/kg, n=1.	[1]
Time to Maximum Concentration (Tmax)	2	h	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 109 ug/kg, n=1.	[1]
Area Under the Concentration-Time Curve (AUC)	58.8	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 109 ug/kg, n=1, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	58.8	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 109 ug/kg, n=1, AUCinf.	[1]

Standard Type	Value	Units	Description	Reference
Area Under the Concentration-Time Curve (AUC)	0.335	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 2.7 ug/kg, n=3, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	0.32±0.49	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 2.7 ug/kg, n=3, AUCinf.	[1]
Volume of Distribution (Vd)	79.1	mL/kg	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 2.7 ug/kg, n=3.	[1]
Area Under the Concentration-Time Curve (AUC)	0.81	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 4.05 ug/kg, n=1, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	0.9	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 4.05 ug/kg, n=1, AUCinf.	[1]
Volume of Distribution (Vd)	48.4	mL/kg	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 4.05 ug/kg, n=1.	[1]
Area Under the Concentration-Time Curve (AUC)	1.16	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 6.075 ug/kg, n=2, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	1.31	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 6.075 ug/kg, n=2, AUCinf.	[1]
Volume of Distribution (Vd)	54.2	mL/kg	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 6.075 ug/kg, n=2.	[1]
Area Under the Concentration-Time Curve (AUC)	6.34	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 12.15 ug/kg, n=1, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	6.67	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 12.15 ug/kg, n=1, AUCinf.	[1]
Volume of Distribution (Vd)	32.2	mL/kg	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 12.15 ug/kg, n=1.	[1]
Area Under the Concentration-Time Curve (AUC)	9.2	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 24.3 ug/kg, n=2, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	9.99	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 24.3 ug/kg, n=2, AUCinf.	[1]
Volume of Distribution (Vd)	49.5	mL/kg	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 24.3 ug/kg, n=2.	[1]
Area Under the Concentration-Time Curve (AUC)	27.7	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 36.45 ug/kg, n=2, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	16.7	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 50 ug/kg, n=2, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	17.8	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 50 ug/kg, n=2, AUCinf.	[1]
Volume of Distribution (Vd)	51.5	mL/kg	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 50 ug/kg, n=2.	[1]
Area Under the Concentration-Time Curve (AUC)	93.3	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 72.9 ug/kg, n=2, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	93.3	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 72.9 ug/kg, n=2, AUCinf.	[1]
Volume of Distribution (Vd)	29.3	mL/kg	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 72.9 ug/kg, n=2.	[1]
Area Under the Concentration-Time Curve (AUC)	89.6	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 78.3 ug/kg, n=1, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	89.6	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 78.3 ug/kg, n=1, AUCinf.	[1]
Volume of Distribution (Vd)	40.6	mL/kg	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 78.3 ug/kg, n=1.	[1]
Area Under the Concentration-Time Curve (AUC)	38	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 99.9 ug/kg, n=2, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	38	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 99.9 ug/kg, n=2, AUCinf.	[1]
Volume of Distribution (Vd)	54.2	mL/kg	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 99.9 ug/kg, n=2.	[1]
Area Under the Concentration-Time Curve (AUC)	58.8	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 109 ug/kg, n=1, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	58.8	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 109 ug/kg, n=1, AUCinf.	[1]
Volume of Distribution (Vd)	42.2	mL/kg	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 109 ug/kg, n=1.	[1]

Standard Type	Value	Units	Description	Reference
Area Under the Concentration-Time Curve (AUC)	0.335	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 2.7 ug/kg, n=3, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	0.32±0.49	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 2.7 ug/kg, n=3, AUCinf.	[1]
Area Under the Concentration-Time Curve (AUC)	0.81	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 4.05 ug/kg, n=1, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	0.9	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 4.05 ug/kg, n=1, AUCinf.	[1]
Area Under the Concentration-Time Curve (AUC)	1.16	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 6.075 ug/kg, n=2, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	1.31	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 6.075 ug/kg, n=2, AUCinf.	[1]
Area Under the Concentration-Time Curve (AUC)	6.34	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 12.15 ug/kg, n=1, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	6.67	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 12.15 ug/kg, n=1, AUCinf.	[1]
Area Under the Concentration-Time Curve (AUC)	9.2	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 24.3 ug/kg, n=2, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	9.99	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 24.3 ug/kg, n=2, AUCinf.	[1]
Area Under the Concentration-Time Curve (AUC)	27.7	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 36.45 ug/kg, n=2, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	16.7	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 50 ug/kg, n=2, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	17.8	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 50 ug/kg, n=2, AUCinf.	[1]
Area Under the Concentration-Time Curve (AUC)	93.3	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 72.9 ug/kg, n=2, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	93.3	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 72.9 ug/kg, n=2, AUCinf.	[1]
Area Under the Concentration-Time Curve (AUC)	89.6	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 78.3 ug/kg, n=1, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	89.6	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 78.3 ug/kg, n=1, AUCinf.	[1]
Area Under the Concentration-Time Curve (AUC)	38	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 99.9 ug/kg, n=2, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	38	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 99.9 ug/kg, n=2, AUCinf.	[1]
Area Under the Concentration-Time Curve (AUC)	58.8	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 109 ug/kg, n=1, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	58.8	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 109 ug/kg, n=1, AUCinf.	[1]

Standard Type	Value	Units	Description	Reference
Area Under the Concentration-Time Curve (AUC)	0.335	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 2.7 ug/kg, n=3, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	0.32±0.49	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 2.7 ug/kg, n=3, AUCinf.	[1]
Elimination Half-Life (t1/2)	6.5	h	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 2.7 ug/kg, n=3.	[1]
Clearance (CL)	8.39	mL/h/kg	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 2.7 ug/kg, n=3.	[1]
Area Under the Concentration-Time Curve (AUC)	0.81	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 4.05 ug/kg, n=1, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	0.9	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 4.05 ug/kg, n=1, AUCinf.	[1]
Elimination Half-Life (t1/2)	7.56	h	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 4.05 ug/kg, n=1.	[1]
Clearance (CL)	4.44	mL/h/kg	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 4.05 ug/kg, n=1.	[1]
Area Under the Concentration-Time Curve (AUC)	1.16	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 6.075 ug/kg, n=2, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	1.31	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 6.075 ug/kg, n=2, AUCinf.	[1]
Elimination Half-Life (t1/2)	8.17	h	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 6.075 ug/kg, n=2.	[1]
Clearance (CL)	4.6	mL/h/kg	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 6.075 ug/kg, n=2.	[1]
Area Under the Concentration-Time Curve (AUC)	6.34	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 12.15 ug/kg, n=1, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	6.67	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 12.15 ug/kg, n=1, AUCinf.	[1]
Elimination Half-Life (t1/2)	12.3	h	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 12.15 ug/kg, n=1.	[1]
Clearance (CL)	1.81	mL/h/kg	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 12.15 ug/kg, n=1.	[1]
Area Under the Concentration-Time Curve (AUC)	9.2	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 24.3 ug/kg, n=2, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	9.99	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 24.3 ug/kg, n=2, AUCinf.	[1]
Elimination Half-Life (t1/2)	14.1	h	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 24.3 ug/kg, n=2.	[1]
Clearance (CL)	2.43	mL/h/kg	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 24.3 ug/kg, n=2.	[1]
Area Under the Concentration-Time Curve (AUC)	27.7	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 36.45 ug/kg, n=2, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	16.7	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 50 ug/kg, n=2, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	17.8	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 50 ug/kg, n=2, AUCinf.	[1]
Elimination Half-Life (t1/2)	12.7	h	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 50 ug/kg, n=2.	[1]
Clearance (CL)	2.81	mL/h/kg	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 50 ug/kg, n=2.	[1]
Area Under the Concentration-Time Curve (AUC)	93.3	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 72.9 ug/kg, n=2, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	93.3	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 72.9 ug/kg, n=2, AUCinf.	[1]
Elimination Half-Life (t1/2)	26.2	h	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 72.9 ug/kg, n=2.	[1]
Clearance (CL)	0.78	mL/h/kg	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 72.9 ug/kg, n=2.	[1]
Area Under the Concentration-Time Curve (AUC)	89.6	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 78.3 ug/kg, n=1, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	89.6	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 78.3 ug/kg, n=1, AUCinf.	[1]
Elimination Half-Life (t1/2)	33	h	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 78.3 ug/kg, n=1.	[1]
Clearance (CL)	0.85	mL/h/kg	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 78.3 ug/kg, n=1.	[1]
Area Under the Concentration-Time Curve (AUC)	38	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 99.9 ug/kg, n=2, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	38	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 99.9 ug/kg, n=2, AUCinf.	[1]
Elimination Half-Life (t1/2)	16.2	h	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 99.9 ug/kg, n=2.	[1]
Clearance (CL)	2.32	mL/h/kg	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 99.9 ug/kg, n=2.	[1]
Area Under the Concentration-Time Curve (AUC)	58.8	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 109 ug/kg, n=1, AUClast.	[1]
Area Under the Concentration-Time Curve (AUC)	58.8	ug*h/mL	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 109 ug/kg, n=1, AUCinf.	[1]
Elimination Half-Life (t1/2)	19	h	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 109 ug/kg, n=1.	[1]
Clearance (CL)	1.54	mL/h/kg	Geometric mean (mean, percentage coefficient of variation [%CV]) pharmacokinetic parameters of ABBV-176 (Q3W schedule first infusion [cycle 1]), 109 ug/kg, n=1.	[1]

Standard Type	NCT Number	Clinical Status	Clinical Trial Description
Undisclosed	NCT03145909	PHASE1	A Phase 1 Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)
Objective Response Rate (ORR)	NCT03145909	Phase 1	A phase 1 study evaluating the safety, pharmacokinetics and anti-tumor activity of ABBV-176 in subjects with advanced solid tumors likely to express prolactin receptor (PRLR).

Standard Type	Value	Units	Cell Line	Disease Model
Tumor Growth Inhibition value (TGI)	≈ 90.5	%	BT-474 cells	Invasive breast carcinoma
Tumor Growth Inhibition value (TGI)	≈ 100	%	BT-474 cells	Invasive breast carcinoma
Tumor Growth Inhibition value (TGI)	≈ 100	%	BT-474 cells	Invasive breast carcinoma

Standard Type	Value	Units	Cell Line	Disease Model
Half Maximal Inhibitory Concentration (IC50)	5.5	pM	T-47D cells	Invasive breast carcinoma
Half Maximal Inhibitory Concentration (IC50)	0.01	nM	22RV1 cells	Prostate carcinoma
Half Maximal Inhibitory Concentration (IC50)	0.01	nM	CAMA-1 cells	Breast adenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	0.11	nM	SW403 cells	Colon adenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	0.16	nM	SMOV-2 cells	Ovarian clear cell adenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	0.24	nM	BT-474 cells	Invasive breast carcinoma
Half Maximal Inhibitory Concentration (IC50)	0.26	nM	SK-BR-3 cells	Breast adenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	0.32	nM	MCF-7 cells	Invasive breast carcinoma
Half Maximal Inhibitory Concentration (IC50)	0.6	nM	AN3-CA cells	Endometrial adenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	0.77	nM	MDA-MB-231 cells	Breast adenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	5.2	nM	Huh-7 cells	Adult hepatocellular carcinoma
Half Maximal Inhibitory Concentration (IC50)	8.6	nM	Hep-G2 cells	Hepatoblastoma
Half Maximal Inhibitory Concentration (IC50)	> 22	nM	MDA-MB-231 cells	Breast adenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	> 22	nM	UACC-812 cells	Invasive breast carcinoma of no special type

Experiment 1 Reporting the Activity Date of This ADC					[2]
Patients Enrolled	Eligibility requires ECOG 0-1 patients with PRLR+ advanced tumors (breast/colorectal/adrenocortical/chromophobe RCC in escalation; breast cancer in expansion) refractory to ≤4 cytotoxic lines, excluding prior PBD agents, uncontrolled comorbidities, significant immunotherapy reactions, active gallbladder disease, major liver resection, or ongoing CTCAE >G1 toxicities, with 21-day washout for most prior therapies (14 days for targeted agents).    Click to Show/Hide
Administration Dosage	ABBV-176 will be administered via intravenous infusion at escalating dose levels until the maximum tolerated dose is reached.
Related Clinical Trial
NCT Number	NCT03145909	Clinical Status	PHASE1
Clinical Description	A Phase 1 Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)
Primary Endpoint	The dose escalation phase evaluates ABBV-176 pharmacokinetics over 57 days and establishes safety parameters (MTD/RPTD) during the first 21-day cycle in PRLR-expressing solid tumors, with expanded cohort assessing ORR per RECIST 1.1 over 2 years.
Other Endpoint	Secondary endpoints include PK monitoring (AUCt, Cmax, Tmax) over 15 days and long-term efficacy outcomes (PFS, DOR, OS up to 2 years) in expanded cohort, alongside ECOG status changes and cardiac safety (QTcF changes over 47 days) in dose escalation phase.
Experiment 2 Reporting the Activity Date of This ADC					[3]
Efficacy Data	Objective Response Rate (ORR)	0%
Patients Enrolled	Locally advanced or metastatic solid tumor types associated with PRLR expression, including breast cancer, colorectal cancer, and adrenocortical carcinoma. Patients had progressed on prior treatment, were not amenable to treatment with curative intent, and had no other therapy options known to provide clinical benefit, or were ineligible for such therapies. Patients had an Eastern Cooperative Oncology Group performance status of 0 or 1, and adequate bone marrow, renal, and hepatic function.    Click to Show/Hide
Administration Dosage	Initial dose was 2.70 ug/kg, dose increment was capped at a 100% increase, or at a 50% increase if a grade2 drug-related toxicity had been observed, intravenously every 21 days.
Related Clinical Trial
NCT Number	NCT03145909	Clinical Status	Phase 1
Clinical Description	A phase 1 study evaluating the safety, pharmacokinetics and anti-tumor activity of ABBV-176 in subjects with advanced solid tumors likely to express prolactin receptor (PRLR).
Primary Endpoint	MtD was not formally determined, as identification of a tolerable dose was confounded by late-onset toxicities. ABBV-176 was associated with significant toxicity in this phase 1, dose-escalation study.
Other Endpoint	No patient had an objective response.

Experiment 1 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 90.50%
Method Description	Mice implanted with BT-474 breast cancer model and dosed with a single dose of ABBV-176 at 0.5 mg/kg.
In Vivo Model	BT-474 CDX
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%
Method Description	Mice implanted with BT-474 breast cancer model and dosed with a single dose of ABBV-176 at 0.1 mg/kg.
In Vivo Model	BT-474 CDX
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100%
Method Description	Mice implanted with BT-474 breast cancer model and dosed with a single dose of ABBV-176 at 0.3 mg/kg.
In Vivo Model	BT-474 CDX
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

Experiment 1 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	5.5 pM
Method Description	The inhibitory activity of ABBV-176 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated 144 hours.
In Vitro Model	Invasive breast carcinoma	T-47D cells		CVCL_0553
Experiment 2 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.01 nM
Method Description	The inhibitory activity of ABBV-176 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated 144 hours.
In Vitro Model	Prostate carcinoma	22RV1 cells		CVCL_1045
Experiment 3 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.01 nM
Method Description	The inhibitory activity of ABBV-176 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated 144 hours.
In Vitro Model	Breast adenocarcinoma	CAMA-1 cells		CVCL_1115
Experiment 4 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.11 nM
Method Description	The inhibitory activity of ABBV-176 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated 144 hours.
In Vitro Model	Colon adenocarcinoma	SW403 cells		CVCL_0545
Experiment 5 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.16 nM
Method Description	The inhibitory activity of ABBV-176 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated 144 hours.
In Vitro Model	Ovarian clear cell adenocarcinoma	SMOV-2 cells		CVCL_S920
Experiment 6 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.24 nM
Method Description	The inhibitory activity of ABBV-176 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated 144 hours.
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 7 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.26 nM
Method Description	The inhibitory activity of ABBV-176 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated 144 hours.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 8 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.32 nM
Method Description	The inhibitory activity of ABBV-176 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated 144 hours.
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 9 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.6 nM
Method Description	The inhibitory activity of ABBV-176 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated 144 hours.
In Vitro Model	Endometrial adenocarcinoma	AN3-CA cells		CVCL_0028
Experiment 10 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.77 nM
Method Description	The inhibitory activity of ABBV-176 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated 144 hours.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 11 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	5.2 nM
Method Description	The inhibitory activity of ABBV-176 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated 144 hours.
In Vitro Model	Adult hepatocellular carcinoma	Huh-7 cells		CVCL_0336
Experiment 12 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	8.6 nM
Method Description	The inhibitory activity of ABBV-176 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated 144 hours.
In Vitro Model	Hepatoblastoma	Hep-G2 cells		CVCL_0027
Experiment 13 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 22 nM
Method Description	The inhibitory activity of ABBV-176 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated 144 hours.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 14 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 22 nM
Method Description	The inhibitory activity of ABBV-176 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated 144 hours.
In Vitro Model	Invasive breast carcinoma of no special type	UACC-812 cells		CVCL_1781

Ref 1	A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors
Ref 2	A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)
Ref 3	A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors. Invest New Drugs. 2020 Dec;38(6):1815-1825.
Ref 4	ABBV-176, a PRLR antibody drug conjugate with a potent DNA-damaging PBD cytotoxin and enhanced activity with PARP inhibition. BMC Cancer. 2021 Jun 9;21(1):681.